glp-1 medication weight loss plateau strategies GLP-1-Based Combination for Loss: Multi-Target Agents and Combination Therapies 3 Takeaways from the Landmark

Smith filed a lawsuit in November of 2023, alleging: As a result of using Defendants Mounjaro, Plaintiff was caused to suffer from gastroparesis, which resulted in, among other things, development of Wernickes encephalopathy. While Eli Lilly has not responded directly in court to their case, it has noted in other filings that Mounjaro labels have always warned that it may be associated with "severe" gastrointestinal reactions

As a result, potential safety concerns might arise in everyday clinical practice that were not evident during the more controlled and structured environment of clinical trial evaluations [Reference Paludetto, Olivier-Abbal and Montastruc28]

They're not a magic bullet, and consistency with diet and exercise remains crucial

3 To understand the relationship between GLP-1 medications and kidney function, as measured by creatinine lab results, we studied 108,439 adult patients who started semaglutide, liraglutide, or tirzepatide between 2021 and 2024 and had one or more creatinine labs in the months leading up to and following the new medication

Superior Blood Sugar Control In head-to-head trials, tirzepatide reduced HbA1c by up to 2.6% compared to semaglutide's 1.9%